Quotient Therapeutics

Quotient Therapeutics is a biotechnology company that has developed a Somatic Genomics platform to analyze genetic variation within the body's cells. The company's primary focus is on identifying somatic mutations—genetic alterations that occur after conception—to understand their role in health and disease. By leveraging high-sensitivity sequencing technology, the platform can detect these variations at the single-cell level, providing insights into the cellular-level mechanisms of various conditions.

The company's business model is centered around the discovery and development of novel therapeutics. By identifying gene variants that confer resistance or vulnerability to disease, Quotient Therapeutics aims to create a pipeline of targeted drugs. The company was launched with a significant $50 million financing from Flagship Pioneering, indicating a business model that relies on venture capital funding for its research and development activities, with the long-term goal of commercializing its therapeutic discoveries or forming partnerships with larger pharmaceutical companies.

Quotient Therapeutics operates in the biotechnology and pharmaceutical markets, specifically within the growing field of genomics and precision medicine. Its approach of studying somatic mutations distinguishes it from companies that focus on inherited genetic variations. The company's services are aimed at addressing unmet medical needs by developing medicines for a wide range of diseases, with the potential to impact any patient population where somatic mutations play a role.

Keywords: somatic genomics, genetic variation, transformative medicines, sequencing technology, drug discovery, precision medicine, biotechnology, cellular genomics, therapeutics, Flagship Pioneering